PatternsRadar
Sign in

HALEOSLABSHALEOS LABS LIMITED

NSE
Full chart
1,587.80INR+38.60 (+2.49%)Close · 6 Oct 2026
5 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹480 CrMarket cap
31.5P/E (TTM)
85.8%Delivery

Filings & corporate actions

38 results filed
CSV
Next results · Q2 FY27
Expected 10 Nov 2026 – 14 Nov 2026
Estimate: filed 41–45 days after quarter end, last 5 times
Dividend
₹1.50 per share · last 23 Sept 2026
2026
  • 23 SeptdividendDividend · ₹1.50 per share+0.7%
  • 5 AugresultsResults · Q1 FY27 · consolidated and standalone-7.3%NSE
  • 7 JulshareholdingShareholding · 30 Jun 2026-0.5%NSE
  • 29 MayresultsResults · Q4 FY26 · consolidated and standalone-10.0%NSE
  • 16 AprshareholdingShareholding · 31 Mar 2026-1.0%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone+0.8%NSE
  • 9 JanshareholdingShareholding · 31 Dec 2025-0.9%NSE

Reaction to results · all yearsrose on day 0 in 15 of 41 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY275 Aug 2026-7.3%-5.7%-3.7%3.7×
Q4 FY2629 May 2026-10.0%-14.2%-7.9%6.8×
Q3 FY2611 Feb 2026+0.8%+1.3%-1.3%1.3×
Q2 FY2610 Nov 2025+3.3%+11.3%+13.9%7.3×
Q1 FY2611 Aug 2025-3.4%-1.3%+5.1%0.2×
Q4 FY2529 May 2025-4.7%-6.8%-14.6%3.4×
Q3 FY2512 Feb 2025+5.0%-0.2%-12.9%0.8×
Q2 FY2514 Nov 2024-5.0%-9.1%+3.4%0.9×
Q1 FY259 Aug 2024+19.1%+15.4%+51.3%40.1×
Q4 FY2427 May 2024+20.0%+1.8%+12.9%30.4×
Q3 FY2410 Feb 2024-5.7%-11.4%-11.1%4.5×
Q2 FY2411 Nov 2023+0.7%+0.7%-0.6%2.4×
Q1 FY248 Aug 2023-2.0%-4.9%+0.8%1.7×
Q4 FY2330 May 2023-3.7%-6.1%-4.7%0.7×
Q3 FY2310 Feb 2023+5.1%+1.3%-8.7%2.2×
Q2 FY2314 Nov 2022-0.1%-2.1%-0.1%0.1×
Q1 FY2310 Aug 2022-1.1%-2.5%+1.5%0.6×
Q4 FY2229 May 2022+1.8%+12.0%+13.6%0.9×
Q3 FY2211 Feb 2022-5.0%-5.1%-0.6%1.9×
Q2 FY2214 Nov 2021-0.4%-3.6%-3.5%0.4×
Q1 FY2213 Aug 2021-1.5%-2.4%-4.0%0.8×
Q4 FY2119 Jun 2021+20.0%+21.2%+10.8%23.2×
Q3 FY2112 Feb 2021-3.1%-8.7%-11.2%0.9×
Q2 FY2113 Nov 2020-4.0%-4.3%+1.4%0.6×
Q1 FY2121 Aug 2020-3.0%-5.3%+38.2%0.7×
Q4 FY2028 Jul 2020-1.9%+38.3%+40.5%0.4×
Q3 FY2015 Feb 2020-11.7%-13.2%-30.6%8.1×
Q2 FY2015 Nov 2019-2.7%-0.2%-8.0%0.7×
Q1 FY2013 Aug 2019-1.2%-5.7%+18.5%0.4×
Q4 FY1927 Jun 2019-1.3%-6.6%-15.7%1.1×
Q3 FY1928 Feb 2019+5.0%+6.2%+5.0%0.9×
Q2 FY1922 Nov 2018+4.7%+4.0%+1.6%1.9×
Q1 FY193 Aug 2018-5.9%-7.0%+7.1%0.7×
Q4 FY1722 Jun 2018-2.1%-4.4%-9.9%0.3×
Q4 FY1822 Jun 2018-2.1%-4.4%-9.9%0.3×
Q3 FY172 Apr 2018+2.6%+11.5%+12.2%0.5×
Q1 FY172 Apr 2018+2.6%+11.5%+12.2%0.5×
Q3 FY189 Feb 2018-0.2%-3.2%-6.9%1.4×
Q2 FY1718 Dec 2017+2.4%+9.3%+8.4%0.6×
Q2 FY1818 Dec 2017+2.4%+9.3%+8.4%0.6×
Q1 FY1826 Sept 2017-4.1%-7.6%-12.7%2.2×
Average+0.1%+0.2%+2.2%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-11.6%
Profit YoY-58.0%
Interest cost YoY-20.7%
Revenue QoQ-2.9%
Profit QoQ+435.0%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+0.1%+1.7%-2.3%+2.5%+6.4%—
Profit-6.0%+42.9%-10.4%+0.8%+12.8%—

Key data

CSV
Open1,560.00
Day range1,560.00 – 1,596.90
52-week range1,091.10 – 1,774.00
From 52w high-10.5%
RSI (14)66.7
ATR (14)53.00
Volume782
Avg volume (20D)932
Rel volume0.84×
Volatility (1Y)40.7%
Turnover₹12.4L
SMA 50 / 2001,492.08 / 1,404.96

Delivery percentage

Latest · 6 Oct 202685.8%
20-day avg80.0%
1-year avg78.1%
Percentile (own history)83rd
Range16.8–100.0%
Sessions1,730

Over the last 20 sessions HALEOSLABS settled 80.0% of its traded quantity, which is unusually high for an NSE equity. That is in line with its own one-year average of 78.1%. The latest session ranks higher than 83% of the 1,730 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+2.49%+4.91%+7.13%-2.01%+26.64%+31.73%

Valuation

CSV
Market cap₹480 Cr
P/E (TTM)31.5
EPS (TTM)50.47
Shares outstanding30.23L
Listed17 Aug 2017

Ownership

CSV
Promoter72.11%
Promoter Δ QoQ0.00 pp
Public27.89%
FII0.00%
DII0.31%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)81.494.875.172.9
YoY chg+3.7%+12.0%-15.7%-11.6%
Net profit (₹ Cr)6.46.60.31.8
YoY chg+94.7%+37.0%-90.1%-58.0%
Net margin7.9%7.0%0.5%2.5%
EPS20.1921.891.448.75

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 72.11% · public 27.89%
31 Mar 2020: promoter 68.00%30 Sept 2021: promoter 67.74%31 Dec 2021: promoter 67.69%31 Mar 2022: promoter 68.96%30 Jun 2022: promoter 69.85%30 Sept 2022: promoter 69.86%31 Dec 2022: promoter 70.32%31 Mar 2023: promoter 70.32%30 Jun 2023: promoter 70.32%30 Sept 2023: promoter 70.32%31 Dec 2023: promoter 70.68%31 Mar 2024: promoter 71.19%30 Jun 2024: promoter 71.41%30 Sept 2024: promoter 71.41%31 Dec 2024: promoter 71.41%31 Mar 2025: promoter 71.41%30 Jun 2025: promoter 71.41%30 Sept 2025: promoter 71.41%31 Dec 2025: promoter 71.80%31 Mar 2026: promoter 72.11%30 Jun 2026: promoter 72.11%
2020-032026-06
  • Promoter
  • Public and others
Promoter
72.11%
Public
27.89%
Promoter change
0.00 pp
Filed
7 Jul 2026
FII
0.00%
DII
0.31%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations69.372.190.092.578.584.689.182.581.494.875.172.9
Other income0.30.62.40.42.00.12.31.00.40.22.00.5
Total income69.672.692.493.080.584.791.583.581.895.077.273.4
Total expenses67.968.885.382.375.877.787.576.573.386.276.270.0
└ Finance costs2.82.32.82.42.12.12.01.91.61.51.41.9
└ Depreciation3.73.73.83.73.83.83.83.83.93.93.84.2
Profit before tax1.73.87.110.64.76.93.97.08.58.80.93.4
Tax expense2.1(0.3)0.63.51.42.10.42.62.12.10.61.6
Net profit(0.4)4.16.57.13.34.93.54.46.46.60.31.8
EPS2.2014.2419.5323.1515.4618.089.8313.7520.1921.891.448.75
Net margin-0.64%5.72%7.19%7.67%4.21%5.74%3.91%5.31%7.90%7.01%0.46%2.52%
PBT margin2.40%5.29%7.89%11.50%6.00%8.18%4.41%8.51%10.44%9.26%1.21%4.72%
Tax rate126.66%-8.21%8.83%33.31%29.84%29.84%11.35%37.58%24.34%24.25%62.01%46.50%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 5 Aug 2026.

HALEOSLABS at a glance

  • HALEOSLABS closed at ₹1,587.8 on 6 Oct 2026, +2.49% on the day, +31.7% over one year, 10.5% below its 52-week high of ₹1,774.
  • Delivery was 85.8% of traded quantity on 6 Oct 2026, the 83rd percentile of its own 1,730 sessions with a reading (20-session average 80.0%, 1-year average 78.1%).
  • Market capitalisation is ₹480 crore at a trailing P/E of 31.5 (trailing EPS ₹50.47).
  • Q1 FY27 results (consolidated, filed 5 Aug 2026): revenue ₹73 crore (-11.6% year on year), net profit ₹2 crore (-58.0%); the price moved -7.3% on the first session after.
  • Promoters held 72.11% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 10 Nov 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE320X01016
SeriesEQ
Listed17 Aug 2017
History from17 Aug 2017
Sessions2,259

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE